HX044 / HanX Biopharma - LARVOL DELTA

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting (PRNewswire) - "Hanx Biopharmaceuticals Ltd...highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25–30). The presentations spotlighted novel bispecific antibodies and a CSF-1R inhibitor, underscoring the company's leadership in innovative cancer treatment strategies."

Clinical data • Solid Tumor

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044 (PRNewswire) - "Hanx Biopharmaceuticals, CO. Ltd...announced the first patient dosing in Australia on Dec 30, 2024 for Phase 1 clinical trial of HX044 in patients with advanced solid tumors (HX044-I-01, A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies, NCT06649708)."

Trial status • Oncology • Solid Tumor

HX044,FIH Study in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Hanx Biopharmaceuticals Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor